09 Sep 2013 Posted in ABPI statement By Press Office
"The strategy rightly acknowledges that the commercial environment for antibiotic development needs to be addressed and that a balanced approach to this challenge requires consideration of new clinical development pathways within a flexible regulatory framework alongside appropriate financial incentives. It is vitally important that a realistic plan of action is agreed so that all partners can work together to deliver upon the strategic objectives that are outlined within the strategy, building on the success of initiatives that are already in train, including the EU Innovative Medicines Initiative collaboration NewDrugs4BadBugs. The role of the High Level Steering Group (HLSG) will be crucial and the ABPI looks forward to engaging with this group, along with other stakeholders."
ABPI Press Office
Tel: +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.